Piramal Pharma Limited (PPLPHARMA) - Total Liabilities
Based on the latest financial reports, Piramal Pharma Limited (PPLPHARMA) has total liabilities worth Rs98.02 Billion INR (≈ $1.06 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Piramal Pharma Limited - Total Liabilities Trend (2021–2026)
This chart illustrates how Piramal Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. See PPLPHARMA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Piramal Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Piramal Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Railway Hi-tech Industry Corp Ltd
SHG:600528
|
China | CN¥34.61 Billion |
|
ChipMOS Technologies
TW:8150
|
Taiwan | NT$20.22 Billion |
|
JOYY Inc
NASDAQ:JOYY
|
USA | $898.33 Million |
|
Zhuzhou Times New Material Technology Co Ltd
SHG:600458
|
China | CN¥18.32 Billion |
|
CHINA CONCH VENT. HD -01
F:68C
|
Germany | €33.41 Billion |
|
Enterprise Financial Services
NASDAQ:EFSC
|
USA | $15.26 Billion |
|
Insignia Financial Ltd
AU:IFL
|
Australia | AU$1.70 Billion |
|
Jiangxi Lianchuang Opto-electronic Science & Technology Co Ltd
SHG:600363
|
China | CN¥3.66 Billion |
Liability Composition Analysis (2021–2026)
This chart breaks down Piramal Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Piramal Pharma Limited market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Piramal Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Piramal Pharma Limited (2021–2026)
The table below shows the annual total liabilities of Piramal Pharma Limited from 2021 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs98.02 Billion ≈ $1.06 Billion |
+29.80% |
| 2025-03-31 | Rs75.52 Billion ≈ $816.73 Million |
+2.05% |
| 2024-03-31 | Rs74.00 Billion ≈ $800.33 Million |
-4.50% |
| 2023-03-31 | Rs77.49 Billion ≈ $838.03 Million |
+27.02% |
| 2022-03-31 | Rs61.00 Billion ≈ $659.74 Million |
+268.37% |
| 2021-03-31 | Rs16.56 Billion ≈ $179.10 Million |
-- |
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, i… Read more